Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C @entity263 : role of adjuvant treatment for XXXX and in disease progression.

@entity1 @entity4742 @entity263 @entity5
A total of 101 @entity1 with limited but unequivocal clinical stage C @entity263 underwent bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. At operation 49 @entity1 had pathological stage C and 52 had stage D1 disease. Followup ranged from 0.5 to 17 years (mean 4.9 years). The 5 and 10-year observed survival rates for @entity1 with stages C and D1 disease were similar to the expected survival. Sixteen @entity1 had @entity5 postoperatively but only 2 had local progression: 1 had received no adjuvant therapy, and 1 had received @entity4742 and radiation. None of the others, having received adjuvant radiation and/or orchiectomy, suffered local recurrence. Over-all, local progression occurred in 17 @entity1 , only 4 of whom had received adjuvant treatment initially ( @entity4742 , 1 also received radiation). Local progression occurred in 13 of 47 @entity1 (28 per cent) without adjuvant treatment. Thus, in all @entity1 immediate adjuvant bilateral orchiectomy or radiation (except for 1 @entity1 ) prevented local progression. In @entity1 with pathological stage D1 disease bilateral orchiectomy significantly reduced disease progression (p less than 0.0001). Therefore, limited clinical stage C @entity263 can be successfully treated surgically (with low morbidity) when supplemented with appropriate immediate adjuvant treatment.
